

999
646

1007

N-[5(S)-3-[4-[4-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]-3,5-difluorofenil]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]acetamida,

N-[5(S)-3-[4-[4-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]fenil]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]acetamida,

1-[5(R)-3-[4-[4-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]fenil]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]-1,2,3-triazol,

4-[5(R)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]-1,2,4-triazol,

5(R)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-5-[(isoxazol-3-il)oxi]metiloxazolidin-2-ona,

5(R)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicciclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-5-[N-(isoxazol-3-il)]aminometiloxazolidin-2-ona,

1000
~~1001~~
~~647~~

N-[5(S)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]ciclopropanocarboxamida,

N-[5(S)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]difluoroacetamida,

1-[5(R)-3-[4-[2-[(1 α , 5 α , 6 β)-3-[(1-Aminociclopropan-1-il)carbonil]-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]-1,2,3-triazol,

o su enantiomero, diastereomero, o sal farmacéuticamente aceptable, hidrato o prodroga de los mismos.

12. El compuesto de acuerdo con la reivindicación 11, que es:

clorohidrato de 1-[5(R)-3-[4-[4-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]-3-fluorofenil]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]-1,2,3-triazol,

1001
~~648~~

1002

clorohidrato de 1-[5(R)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]-1,2,3-triazol,

clorohidrato de N-[5(S)-3-[4-[4-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]-3-fluorofenil]fenil]-2-oxooxazolidin-5-ilmetil]acetamida,

clorohidrato de N-[5(S)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]fenil]-2-oxooxazolidin-5-ilmetil]acetamida,

clorohidrato de N-[5(S)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]-3-fluorofenil]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]acetamida, o

Clorohidrato de N-[5(S)-3-[4-[2-[(1 α , 5 α , 6 β)-6-Ciano-3-azabicyclo[3.1.0]hexan-6-il]piridina-5-il]-3-fluorofenil]-2-oxooxazolidin-5-ilmetil]acetamida.

13. Una composición farmacéutica compuesta por un compuesto de acuerdo con la reivindicación 1 en combinación con un portador farmacéuticamente aceptable, dicha composición opcionalmente en combinación con una vitamina seleccionada del grupo formado por vitamina B2, vitamina B6, vitamina B12 y ácido fólico.

1002
149

1003

14. Un método para tratar o prevenir una infección bacterial o un efecto colateral asociado con oxazolidina en un paciente mamífero que necesita dicha compuesto que comprende administrar a un paiente una cantidad efectiva del compuesto de la reivindicación 1 y opcionalmente una cantidad efectiva de una o más vitaminas seleccionadas del grupo formado por vitamina B2, vitamina B6, vitamina B12 y ácido fólico a un paciente que las necesita.

15. Un método de acuerdo con la reivindicación 14, caracterizado porque el efecto colateral asociado con la oxazolidinona es anemia normocítica, anemia sideroblástica, neuropatía sensorial periférica, neuropatía óptica, apoplejía, trombocitopenia, queilosis, dermatitis seborreica, anemia hiporregenerativa o anemia megaloblástica.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF RECEIPT OF
RECORD COPY

(PCT Rule 24.2(a))

From the INTERNATIONAL BUREAU

To:

TOFFENETTI, Judith, L.
McDermott, Will & Emery LLP
600 13th Street, N.W.
Washington, DC 20005-3096
United States of America

Date of mailing (day/month/year)

22 September 2004 (22.09.2004)

IMPORTANT NOTIFICATION

Applicant's or agent's file reference

50193-187

International application No.

PCT/US2004/020734

The applicant is hereby notified that the International Bureau has received the record copy of the international application as detailed below.

Name(s) of the applicant(s) and State(s) for which they are applicants:

MERCK & CO., INC. et al (for all designated States except US)

FUKUDA, Yasumichi (for US)

International filing date

: 29 June 2004 (29.06.2004)

Priority date(s) claimed

: 02 July 2003 (02.07.2003)

24 February 2004 (24.02.2004)

Date of receipt of the record copy
by the International Bureau

: 01 September 2004 (01.09.2004)

List of designated Offices

:

AP : BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW

EA : AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP : AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

OA : BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

National : AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,

LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,

SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

2004-09-01
OCT - 6 2004
SWITZERLAND

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 338.89.85

Authorized officer:

Leslie BARRIOS (Fax 338 8970)

Telephone No. (41-22) 338 8716

Continuation of Form PCT/IB/301

NOTIFICATION OF RECEIPT OF RECORD COPY

1004/65

1005

Date of mailing (day/month/year) 22 September 2004 (22.09.2004)	IMPORTANT NOTIFICATION
Applicant's or agent's file reference 50193-187	International application No. PCT/US2004/020734

ATTENTION

The applicant should carefully check the data appearing in this Notification. In case of any discrepancy between these data and the indications in the International application, the applicant should immediately inform the International Bureau.

In addition, the applicant's attention is drawn to the information contained in the Annex, relating to:

- ☒ time limits for entry into the national phase - see updated important information (as of April 2002)
- ☒ requirements regarding priority documents (if applicable)

A copy of this Notification is being sent to the receiving Office and to the International Searching Authority.